Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldstein

Showing results (481-490 of 518) with videos related to

Pageof 52
Sort By:
Nature Genetics|January 10, 2017
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomasSimon Papillon-Cavanagh, Chao Lu, Tenzin Gayden, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Cancers|September 9, 2023
A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature ReviewArwa Abdelmogod, Lia Papadopoulos, Stephen Riordan, et al.
International Journal of Cancer|June 30, 2026
HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal CancerLucas Penny, Eric Yang Stutheit-Zhao, Birgitta E Michels, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
Space Science Reviews|February 10, 2025
Mass Supply from Io to Jupiter's MagnetosphereLorenz Roth, Aljona Blöcker, Katherine de Kleer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|December 2, 2021
The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancerAshika D Maharaj, Sue M Evans, Liane J Ioannou, et al.
Pageof 52

Showing results (481-490 of 518) with videos related to

Sort By:
Pageof 52
Nature Genetics|January 10, 2017
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomasSimon Papillon-Cavanagh, Chao Lu, Tenzin Gayden, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
Cancers|September 9, 2023
A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature ReviewArwa Abdelmogod, Lia Papadopoulos, Stephen Riordan, et al.
International Journal of Cancer|June 30, 2026
HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal CancerLucas Penny, Eric Yang Stutheit-Zhao, Birgitta E Michels, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
Space Science Reviews|February 10, 2025
Mass Supply from Io to Jupiter's MagnetosphereLorenz Roth, Aljona Blöcker, Katherine de Kleer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJuan W Valle, Daniel Palmer, Richard Jackson, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|December 2, 2021
The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancerAshika D Maharaj, Sue M Evans, Liane J Ioannou, et al.
Pageof 52